Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes
Aiwen Li(Amgen (United States)), Christopher Fotsch(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Minghan Wang(Shanghai Ninth People's Hospital), Xiping Zhang(Amgen (United States)), Clarence Hale(Amgen (United States)), David J. St. Jean(Amgen (United States)), Renée Komorowski(Amgen (United States)), Maurice G. Emery(Amgen (United States)), Michelle Chen(Broad Institute), Chester Yuan(Amgen (United States)), David Chow(Amgen (United States)), Murielle M. Véniant(Amgen (United States))
Cited by 21
Related Papers
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Comparison of Information-Dependent Acquisition, SWATH, and MS<sup>All</sup> Techniques in Metabolite Identification Study Employing Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry
|Analytical Chemistry|2013|211
Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry
|Journal of Mass Spectrometry|2006|153